Beacon Harbor Wealth Advisors Boosts Incyte Corporation Holdings

The investment firm acquired a new stake in the biopharmaceutical company during Q4 2025.

Apr. 12, 2026 at 7:37am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, industrial-looking financial machinery and equipment, conveying a sense of the institutional power and infrastructure behind modern investment decisions.Beacon Harbor Wealth Advisors' sizable new investment in Incyte Corporation reflects growing confidence in the biopharmaceutical firm's future.Wilmington Today

Beacon Harbor Wealth Advisors Inc. acquired a new stake of 68,069 shares in Incyte Corporation (NASDAQ:INCY) during the fourth quarter of 2025, valued at approximately $6.7 million. This represents about 1.5% of Beacon Harbor's total holdings, making Incyte the firm's 28th largest position.

Why it matters

The investment by Beacon Harbor Wealth Advisors in Incyte Corporation reflects growing institutional interest in the biopharmaceutical company, which develops and commercializes novel therapies for oncology, inflammation, and rare diseases. Incyte's flagship product is the JAK inhibitor Jakafi, approved for the treatment of myelofibrosis and polycythemia vera.

The details

Beacon Harbor Wealth Advisors acquired 68,069 shares of Incyte Corporation in the fourth quarter of 2025. This new stake represents approximately 1.5% of the firm's total holdings, making Incyte its 28th largest position. Other major investors that have recently increased their positions in Incyte include AQR Capital Management, Pacer Advisors, and Caisse de dépôt et placement du Québec.

  • Beacon Harbor Wealth Advisors acquired the new Incyte stake in Q4 2025.

The players

Beacon Harbor Wealth Advisors Inc.

An investment management firm that acquired a new stake in Incyte Corporation during the fourth quarter of 2025.

Incyte Corporation

A biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies in oncology and inflammation. Its flagship product is the JAK inhibitor Jakafi.

Got photos? Submit your photos here. ›

The takeaway

The investment by Beacon Harbor Wealth Advisors in Incyte Corporation reflects growing institutional interest in the biopharmaceutical company and its portfolio of innovative therapies, particularly its flagship product Jakafi. This move highlights Incyte's position as a key player in the oncology and inflammation treatment landscape.